histamine H3 receptor tone

Every compound in the sci-wiki that affects histamine h3 receptor tone; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

0 sourced · 2 reference

←histamine h3 receptor tone2/2

Nootropic

ABT-239

Abbott Laboratories built ABT-239 as a drug-like, orally active histamine H3 antagonist with real human-development ambitions behind it, unlike most H3 tool compounds; it was investigated as a candidate for ADHD, Alzheimer's disease, and schizophrenia-related cognitive deficits. It bound the human H3 receptor with subnanomolar potency and more than 1000-fold selectivity over the other histamine receptor subtypes, and it worked in rodent cognition and stress models. Abbott dropped it from human trials after it showed QT interval prolongation, a cardiac liability serious enough to end clinical plans outright, and ABT-239 has since lived on purely as a widely used preclinical benchmark for newer H3 antagonists.

reference

Nootropic

Bavisant

Bavisant started life at Johnson & Johnson as JNJ-31001074, a potent, brain-penetrant histamine H3 antagonist aimed at adult ADHD; a controlled dose-ranging trial found it did not produce a clinically meaningful benefit over placebo, and J&J's ADHD program quietly closed. The molecule's story did not end there. BenevolentAI, an AI-driven drug discovery company, later licensed the same compound, renamed it bavisant, and repositioned it around a side effect noted in the original data, dose-dependent insomnia, betting that the same wake-promoting H3 blockade could help excessive daytime sleepiness in Parkinson's disease instead. That reran the drug through a Phase IIb trial testing three doses against placebo in roughly 230 Parkinson's patients, an unusually direct case of an abandoned CNS candidate getting a second clinical life through indication-hopping rather than fresh chemistry.

reference